Webinar: Clinical value of cystatin C in drug dosing

Clinical value of predicting renal elimination of medications with cystatin C

Welcome to the fourth webinar in Gentian's cystatin C webinar series. Our US Product Specialist, Shanyil Wickramasinghe, will focus on two real-world scenarios to illustrate the clinical value of incorporating cystatin C testing into medication dosing and monitoring protocols:

• Personalising chemotherapeutic interventions through co-reporting of cystatin C and creatinine-based eGFRs

• Cystatin C-guided dosing of vancomycin: A novel approach to achieving trough concentrations among ICU patients

Data presented in this webinar is collected from publications of independent research^1-10.

Watch the webinar here: 

Watch webinar here

References:

1. McMahon, BA and MH Rosner. GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer, in Kidney360, 2020. 1: p. 141-150.
2. Santos, MLC et al. Nephrotoxicity in cancer treatment: An overview, in World J Clin Oncol, 2020. 11(4): p. 190-204.
3. Orth, M et al. Avoiding Insufficient Therapies and Overdosing with Co-Reporting eGFRs for Personalized Drug Therapy and Improved Outcomes, in ACHIEVING MEASURABLY BETTER HEALTHCARE PERFORMANCE, 2019.
4. Frazee, EN et al. Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study, in Crit Care, 2014. 18(3): p. R110.
5. Begg, EJ, ML Barclay and CJ Kirkpatrick. The therapeutic monitoring of antimicrobial agents, in Br J Clin Pharmacol, 1999. 47(1): p. 23-30.
6. Levine, DP. Vancomycin: a history, in Clin Infect Dis, 2006. 42 Suppl 1: p. S5-12.
7. FDA, Guidance for Industry Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data Analysis, and Impact on Dosing, DHHS, Editor. 2020: www.fda.gov.
8. Frazee, E et al. Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project, in Am J Kidney Dis, 2017. 69(5): p. 658-666.
9. Kullar, R et al. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort, in Pharmacotherapy, 2012. 32(3): p. 195-201.
10. Lloyd-Smith, P et al. Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: assessing attributable cost and length of stay, in J Hosp Infect, 2013. 85(1): p. 54-